MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways

Ruitao Zhang*, Huirong Shi, Fang Ren, Wei Feng, Yuan Cao, Gailing Li, Zheying Liu, Pengcheng Ji and Minghui Zhang

Abstract

Background: Downregulation of microRNA-338-3p (miR-338-3p) was detected in many malignant tumors, which indicated miR-338-3p might serve as a role of antioncogene in those cancers. The present study aimed to explore the roles of miR-338-3p in the growth and metastasis of ovarian cancer cells and elaborate the underlying possible molecular mechanism.

Methods: Multiply biomedical databases query and KEGG pathway enrichment assay were used to infiltrate possible target genes and downstream pathways regulated by miR-338-3p. Overexpression miR-338-3p lentiviral vectors were transfected into ovarian cancer OVCAR-3 and OVCAR-8 cells, cell proliferation, migration and invasion were analyzed by MTT, colony formation, transwell, Matrigel assay and xenograft mouse model. One 3′-untranslated regions (UTRs) binding target gene of miR-338-3p, MACC1 (MET transcriptional regulator MACC1), and its regulated gene MET and downstream signaling pathway activities were examined by western blot.

Results: Biomedical databases query indicated that miR-338-3p could target MACC1 gene and regulate Met, downstream Wnt/Catenin beta and MEK/ERK pathways. Rescue of miR-338-3p could inhibit the proliferation, migration and invasion of ovarian cancer cells, and suppress the growth and metastasis of xenograft tumor. Restoration of miR-338-3p could attenuate MACC1 and Met overexpression induced growth, epithelial to mesenchymal transition (EMT) and activities of Wnt/Catenin beta and MEK/ERK signaling in vitro and in vivo.

Conclusions: The present data indicated that restoration of miR-338-3p could suppress the growth and metastasis of ovarian cancer cells, which might due to the inhibition of proliferation and EMT induced by MACC1, Met and its downstream Wnt/Catenin beta and MEK/ERK signaling pathways.

Keywords: miR-338-3p, Ovarian cancer, MACC1, Met, Growth, Metastasis

Background

Sustaining proliferative signaling and activating invasion and metastasis are two important malignant hallmarks of human cancer [1], which also can be observed in ovarian cancer, especially in advanced ovarian cancer. Extensive disseminated growth and distant metastasis in the pelvic and abdominal cavity are the most important malignant biological characteristics of advanced ovarian cancer. Target therapy, cell cycle regulator and immunotherapy methods, like PARP and CDK4/6 inhibitors and PD-1 or PD-L1 antibodies, are effective complements of Platinum-based combination chemotherapy after cytoreductive surgery and new exciting therapeutic ways to prolong the survival time for chemoresistance and recurrence ovarian cancer patients [2–4]. However, ovarian cancer still is the most lethal gynecological malignancy [5]. Inhibition of malignant abilities, like endless proliferation and activating invasion and metastasis, seems to be
the fundamental way to solve this troublesome problem in ovarian cancer. Therefore, explore the molecular mechanism of malignant growth and metastasis might provide new therapy strategies for ovarian cancer.

MicroRNAs (miRNAs), earliest discovered non-coding RNAs, are well demonstrated to be implicated in the cell proliferation, invasion and metastasis of almost all types of human cancers [6]. Emerging evidences showed upregulation of miR-338-3p could target different downstream genes and signaling pathways to inhibit malignant cells proliferation, migration and invasion in rectal cancer, gastric cancer, lung cancer, neuroblastoma and liver cancer, which indicated miR-338-3p might be associated with the initiation and progression of these human cancers [7–11]. Only few researches involved in the relation between miR-338-3p and ovarian cancer. One study indicated miR-338-3p could inhibit the proliferation and metabolism of ovarian cancer, and the other showed miR-338-3p could suppress growth of ovarian epithelial carcinoma cells by targeting Runx2 [12, 13]. We previously reported miR-338-3p was decreased and negatively related with MACC1 (MET transcriptional regulator MACC1) in epithelial ovarian cancer tissues [14]. Thence, the roles of miR-338-3p involved in ovarian cancer still need more research.

In present study, we overexpressed miR-338-3p, MACC1, one 3′-untranslated regions (UTRs) binding target gene of miR-338-3p, and its regulated gene MET in ovarian cancer cells respectively to explore the effects on proliferation, epithelial to mesenchymal transition (EMT) and downstream pathways in vitro and in vivo, and to elaborate the roles of miR-338-3p in the growth and metastasis of ovarian cancer.

Methods

Biomedical database query

Multiply biomedical databases, including dbDEMC [15], cBioPortal [16], One mil [17], miRTarBase [18], TargetScan Human [19], microT-CDS [20], miPathDB [21] and miRTarBase [22] were queried to examine the expressions of miR-338-3p in ovarian cancer tissues and to filter its possible target genes.

KEGG pathway enrichment analysis

KEGG database (Previous version named starBase database, http://starbase.sysu.edu.cn/) was used to perform Kyoto encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis for miR-338-3p, MACC1 and Met to filter downstream regulation pathways.

Cell culture and reagents

The ovarian cancer cell lines SKOV3, OVCAR3 and A2780 were obtained from China Center for Type Culture Collection (CCTCC) and OVCAR8 cells were obtained from American Type Culture Collection (ATCC), which were cultured in DMEM or RPMI 1640 medium. Immortalized human ovarian epithelial cells SV40 were obtained from Applied Biological Materials Inc. (Richmond, Canada) and cultured in Prigrow I medium (Abm, Richmond, Canada). Mentioned cell culture mediums were supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (Hyclone, Logan, UT). HEK293FT cells were purchased from Thermo Fisher Scientific Inc. (Waltham, Massachusetts, USA) and cultured in DMEM medium with 10% FBS, 0.1 mM non-essential amino acids, 6 mM L-glutamine, 1 mM Sodium Pyruvate and 1% Pen-Strep. All cells were maintained in 5% Carbon dioxide, 37.0 °C and 95% humidity incubator. Cells were cleared of mycoplasma contamination.

Wnt/Catenin beta signaling inhibitor IWP-2 and MEK/ERK signaling inhibitor U0126 were purchased from Beyotime Biotechnology (Shanghai, China).

Lentiviral vector and transfection

Lentiviral miRNA control vectors, which were used to construct miR-338-3p overexpression lentivectors and were sequenced by RiboBio (Guangzhou, China), MACC1 and Met overexpression and control lentivectors were obtained from Abm Inc. (Richmond, Canada). All lentivectors were packaged in HEK293FT cells by lentivirus packaging mix (Abm, Richmond, Canada) following the protocol of manufacturer. Lentivectors were purified and transfected into OVCAR3 and OVCAR8 cells with polybrene, stable pools of transfected cells were selected with 5 μg/ml puromycin.

Real time PCR

Cell total RNA were isolated by Trizol reagent (Invitrogen, Carlsbad, Calif., USA), 2 μg total RNA were used to reverse-synthesize cDNA template following the TaqMan MicroRNA Reverse Transcription kit instructions (Applied Biosystems Co., Ltd. USA) for SYBR Green PCR (Takara, Carlsbad, Calif., USA) assay. The PCR primers and reaction conditions were produced as described previously, and expression of miR-338-3p was normalized to U6 [14]. Each PCR experiment was performed for three times independently, and the relative expression value was expressed by 2−ΔΔCt method.

Western blot

The antibodies used in Western blot assay were glyceraldehyde 3-phosphate dehydrogenase (GAPDH, AF0006), Met (AF0120), proliferating cell nuclear antigen (PCNA, AF0261), MMP2 (AF0234), E-cadherin (AF0138), Cytokeratin7 (AF0129), N-cadherin (AF0243), Vimentin (AF0318), Catenin beta (AF0069), t-MEK1/2 (AF1057), p-MEK1 (AF1786), t-ERK1/2 (AF1051), p-ERK1/2 (AM071) (Beyotime Biotechnology, Shanghai, China), and MACC1 (86,290 s), MMP9 (13,667 s), Wnt3a (2391 s), p-LRP6
(2568s), LRP6 (3395s) (Cell Signaling, Danvers, USA). Total protein was collected by RIPA buffer (Beyotime Biotechnology, Shanghai, China) containing proteinase inhibitor, equal amount of protein (50 μg per lane) was used to perform 8–10% SDS-PAGE separation and immunoblot as described previously [23].

**Dual-luciferase reporter assay**

Wild type and mutant type MACC1 3'UTR binding sites of hsa-miR-338-3p were cloned into pMIR-GLO™ Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI, USA) by Ribobio (Guangzhou, China). OVCAR3 and OVCAR8 cells were planted into 96-well plate in triplicate for 24 h, and co-transfected with wild type or mutant type MACC1 3'UTR vectors together with miR-338-3p overexpression or control lentivectors. After incubation for another 48 h, luciferase activities were measured using dual-luciferase reporter assay system (Promega, Madison, WI, USA) following the manufacturer’s protocol. Renilla luciferase activities were used as normalization.

**MTT assay**

Planted 1 × 10⁴ cells per well into 96-well plates, five duplicate wells were set up for each group. Cultured cells continuously for 3 days, added 20 μl MTT reagents (5 mg/mL, Sigma, St. Louis, USA) into each well, incubated for another 4 h then aspirated former medium and added 150 μl DMSO. The absorbances of sample were measured by Microplate spectrophotometer (Thermo, Spectronic, Madison, WI, USA) at 490 nm.

**Cell colony formation assay**

Cells (300 per well) were plated into 6-well plate in triplicate for 10 days culture, stained cells with 0.1% Crystal Violet after fixation in methanol for 20 min, and cell colonies with more than 50 cells were counted using Image J software.

**Cell migration assay**

Cells were pretreated with serum free medium for 24 h, 3 × 10⁵ cells in 300 μl serum free medium were added into the upper transwell chamber (BD Falcon, San Jose, CA). 700 μl medium with 10% FBS was added into each well when the chambers were inserted. After incubation for another 16 h, the chamber membranes were fixed with methanol for 20 min and stained with crystal violet for 15 min. Cells on the lower membranes in at least three different fields were counted under 10× magnification.

**Cell invasion assay**

Except for the following steps, other processes were the same as the transwell migration assay. Chambers used for invasion assay were precoated with Matrigel (BD Bioscience), cells were incubated for another 36 h after planting and the transwell inserts were stained by H&E method.

**Mouse xenograft model**

Animal experiment protocols were approved by the ethics committee of the first affiliated hospital of Zhengzhou University. Eight two-month-old female NOG, NOG-CrPrkdc<sup>−/−</sup>L2rg<sup>−/−</sup>/JicCrl) mice (Charles River, Beijing, China) were randomly divided into two groups with four mice in each group. Control and stable miR-338-3p overexpression lentivectors transfected OVCAR-8 cells (1 × 10⁶ cells in 10 μl PBS per mouse) labeled with luciferase lentivectors were injected into the peritoneum after Isoflurane inhalation anesthesia. Tumor initiation and progression were monitored once a week using an IVIS Spectrum system (Xenogen, California Sciences). All mice were sacrificed at the fourth week after cell inoculation.

**Immunohistochemistry**

Xenograft tumor tissues were fixed in formalin, embedded in paraffin and sectioned at 3 μm for immunohistochemistry assay. Expressions of MACC1, Met, PCNA, E-cadherin and Catenin beta were detected by broad spectrum immunohistochemistry SP kit and metal enhanced DAB substrate kit (Solarbio, Beijing, China) following manufacture’s protocol. Protein relative positive ratios were measured by Image J software in at least three independent fields.

**Statistical analysis**

Significant differences were determined with one-way analysis of variance (one-way ANOVA) and Student’s t-test by SPSS 21.0 and GraphPad Prism 7.0 software packages, data were presented as mean ± SD. P-values less than 0.05 were regarded as statistically significant, while the values ** P < 0.01 and *** P < 0.001 were considered to indicate increased statistical significance.

**Results**

miR-338-3p was downregulated in ovarian cancer tissues and could target MACC1

The expression profiles of miR-338-3p in ovarian cancer queried in multiply biomedical databases well confirmed to our previous report [14]. Compared to 7 cases normal fallopian samples, miR-338-3p and other 174 miRNAs were decreased in 114 high-grade and advanced stage epithelial ovarian, primary peritoneal or fallopian tube serous carcinoma tissue samples detected by whole-genome characterization assay (Fig. 1a). In three independent TCGA cohort data with total 1680 ovarian serous adenocarcinoma tissue samples, most samples could not detect miR-338-3p alteration, 4 cases detected deep deletions, and only 69 cases detected amplifications,
which also showed an expression profile negative related to MACC1 (Fig. 1b,c). Down-regulations of miR-338-3p in ovarian cancer tissues were also detected in OncomiR database (Fig. 1d). These data showed expression profile of miR-338-3p was downregulated in ovarian cancer tissues.

MACC1 was 1 of 15 target genes of miR-338-3p with strong support showed by miRTargetLink database (Fig. 1e). Based on multiply database interactive verification, miR-338-3p could bind to the 3’-UTRs of MACC1 and MACC1 was one of downstream target genes of miR-338-3p (Fig. 1f, Additional file 2) which was also
demonstrated by several independent reports in different cancer cells using dual-luciferase reporter assay or biotin-avidin pull-down assay [24–29]. Therefore, MACC1 should be one of downstream target genes of miR-338-3p.

**miR-338-3p could regulate Met, Wnt/Catenin beta and MEK/ERK pathways**

Indicated by mir-Tar-pathway analysis in ENCORI database, miR-338-3p could regulate 328 genes of KEGG pathways in cancer (log10 FDR: −9.52602, log10 p value: −11.79554), including MET, WNT3A, CTNNB1 (Catenin beta), MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK1 (ERK2), MAPK3 (ERK1), MMP2, MMP9 and CDH1 (E-cadherin). When referred to mta-Tar-pathway analysis, MET could regulate 75 genes of KEGG adherens junction pathways (log10 FDR: −1.65161, log10 p value: −3.23139), including MAPK1 (ERK2), MAPK3 (ERK1), CTNNB1 (Catenin beta) and CDH1 (E-cadherin). More detail data were shown in Additional file 1. These data indicated miR-338-3p could regulate Met, Wnt/Catenin beta and MEK/ERK pathways.

**miR-338-3p was decreased in ovarian cancer cells**

To confirm the expression profiles in ovarian cancer tissues, expressions of miR-338-3p were examined in different ovarian cancer cells by real time PCR in present study. Compared to normal ovary epithelial cells, down-regulated miR-338-3p was detected in ovarian cancer SKOV3, OVCAR3, A2780 and OVCAR8 cells (Fig. 2a) which indicated the expression profile of miR-338-3p was also decreased in ovarian cancer cells.

**Confirmation of lentiviral vectors transfection effects in ovarian cancer cells**

Before malignant behavior assay, lentivectors transfection consequences were confirmed firstly. After 72 h puromycin treatment, total mRNA and protein of stable transfection cells were isolated for analysis. Compared to blank cells and control lentivectors transfected cells, levels of miR-338-3p were significantly upregulated after overexpression vectors transfection (Fig. 2b). Furthermore, MACC1 and Met overexpression lentivectors transfection effectively elevated MACC1 and Met levels in ovarian cancer cells respectively (Fig. 2c, d).

**miR-338-3p could directly target MACC1 in ovarian cancer cells**

To confirm the direct interaction between miR-338-3p and MACC1, we performed dual-luciferase reporter assay following co-transfection wild type and mutant type MACC1 3′-UTR vectors with miR-338-3p overexpression or control lentivectors (Fig. 2e) in ovarian
cancer cells. In OVCAR3 and OVCAR8 cells, lower luciferase activities were observed in wild type MACC1 3′-UTR and miR-338-3p overexpression vectors co-transfected cells compared with mutant type, which indicated mutation of the target site in the MACC1 3′-UTR abolished the inhibition of luciferase activity by miR-338-3p (Fig. 2f). Furthermore, expressions of MACC1 and Met were obviously downregulated after miR-338-3p overexpression in ovarian cancer cells (Fig. 2g). Therefore, our data confirmed that MACC1 was one directly target gene of miR-338-3p in ovarian cancer cells.

**Restoration of miR-338-3p inhibited the proliferation of ovarian cancer cells**

Cell proliferation OD values and cell colony numbers decreased after miR-338-3p restoration in ovarian cancer cells. MACC1 or Met overexpression could increase cell proliferation OD values and cell colony numbers, but those proliferation promotive effects could be attenuated by miR-338-3p overexpression, at least partially (Fig. 3), which showed miR-338-3p could inhibit the proliferation of ovarian cancer cells induced by MACC1 and Met overexpression.

**Restoration of miR-338-3p suppressed the migration and invasion of ovarian cancer cells**

Compared to control cells, decreased migration and invasion cell numbers were observed in transwell assay after rescue of miR-338-3p. MACC1 or Met overexpression could increase migration and invasion cell numbers, which also could be restrained following miR-338-3p overexpression (Fig. 4). Weakened aggressive cell phenotypes were also observed in miR-338-3p restoration cells (Fig. 5) in vitro. These data indicated miR-338-3p could suppress the migration and invasion abilities of ovarian cancer cells.

**Restoration of miR-338-3p repressed xenograft tumor growth and metastasis**

Before ovarian cancer cells inoculated mice sacrifice, the intensities of luminescence were measured for the last time. Compared to control cells induced tumors, the intensities of luminescence in miR-338-3p overexpression cells induced xenograft tumor were obviously decreased (Fig. 6a), as well as the tumor weights (Fig. 6b), which showed miR-338-3p enabled an inhibitory effect on the ovarian cancer cells induced tumor growth. Attenuated aggressiveness and metastasis of ovarian cancer cells

---

**Fig. 3** Restoration of miR-338-3p inhibited the proliferation of ovarian cancer cells. Cell proliferation detected by MTT assay **a** and colony formation assay **b** in control, miR-338-3p overexpression, MACC1 overexpression, Met overexpression, miR-338-3p overexpression + MACC1 overexpression and miR-338-3p overexpression + Met overexpression lentivectors transfected OVCAR3 and OVCAR8 cells respectively.
were also observed in the ovary, liver and spleen tissue. H&E staining sections of miR-338-3p restored mice tumors (Fig. 6c). These data suggested miR-338-3p could repress the growth and metastasis of ovarian cancer cell xenograft tumors.

**Restoration of miR-338-3p restrained MACC1 and Met induced proliferation and EMT in vitro**

Furthermore, we explored the possible mechanism of miR-338-3p induced inhibition of ovarian cancer cells growth and metastasis. Due to the recovery of miR-338-3p expression, MACC1 and Met expressions were downregulated in ovarian cancer cells. Upregulations of MACC1 or Met induced by MACC1 or Met overexpression lentivectors transfection could be attenuated when transfected miR-338-3p overexpression lentivectors simultaneously into ovarian cancer cells (Fig. 7a-b). Cell proliferation and EMT related proteins were also measured to explore the roles of miR-338-3p in cell proliferation and EMT. After restoration of miR-338-3p, expressions of PCNA, MMP2 and MMP9 (also two target genes of miR-338-3p indicated by miRTargetLink database, Fig. 1e) were downregulated, as well as the expressions of N-cadherin, Vimentin and Catenin beta, while expressions of E-cadherin and Cytokeratin7 were upregulated. Furthermore, MACC1 or Met overexpression could induce downregulations of E-cadherin and Cytokeratin7, and upregulations of PCNA, MMP2, MMP9, N-cadherin, Vimentin and Catenin beta, but could be...
Fig. 6 Restoration of miR-338-3p repressed xenograft tumor growth and metastasis. 

a The intensities of luminescence in control and miR-338-3p overexpression OVCAR8 cells induced mice xenograft tumors; b The weights of sacrificed mice left ovary xenograft tumors; c Xenograft tumor and metastasis tumor observed in the ovary, liver and spleen tissue H&E staining sections from mice xenograft model.
attenuated by the restoration of miR-338-3p (Fig. 7a-d). Therefore, miR-338-3p could restrain the proliferation and EMT of ovarian cancer cells induced by MACC1 and Met overexpression.

Restoration of miR-338-3p inhibited the activities of Wnt and MEK signaling induced by MACC1 or Met overexpression in vitro

Based on KEGG pathway assay, we detected the activities of canonical Wnt/Catenin beta and MEK/ERK pathways. As consequences of MACC1 or Met overexpression, levels of Wnt3a and p-LRP6, p-MERK1/2 and p-ERK1/2 were elevated, which could be attenuated by Wnt signaling inhibitor IWP-2 and MEK signaling inhibitor UO126 treatment respectively. Similar inhibitory effects were observed in control, MACC1 and Met overexpressed ovarian cancer cells following miR-338-3p restoration, which indicated miR-338-3p could attenuate MACC1 or Met induced Wnt and MEK signaling activities, at least in partially (Fig. 7e-h).

Restoration of miR-338-3p suppressed proliferation, EMT, Wnt and MEK signaling in vivo

Total mRNA and protein from xenograft tumor tissues were also extracted after animal sacrifice. Upregulations of miR-338-3p, E-cadherin and Cytokeratin7, downregulations of MACC1, Met, PCNA, MMP2 and MMP9 in control, miR-338-3p overexpression, MACC1 overexpression, Met overexpression, miR-338-3p overexpression + MACC1 overexpression and miR-338-3p overexpression + Met overexpression lentivectors transfected OVCAR3 and OVCAR8 cells respectively. e-h Activities of Wnt/Cadherin beta and MEK/ERK pathways examined by western blot in different groups, Wnt signaling inhibitor (30 μM IWP-2) and MEK signaling inhibitor (1 μM UO126) were used to treat control, MACC1 overexpression and Met overexpression cells for 24 h as a positive control.
Discussion

Based on the progresses of understanding the biology of human cancer, other well-known human cancer hallmarks are considered to collaborate to ensure tumor cells growth and metastatic dissemination [1]. Endless proliferation enables enough cell numbers to escape from the elimination of the body protection systems, and distant metastasis not only bases on enough cancer cell numbers but also provides new places for malignant cell growth. Both the two aggressive behaviors distinctively characterize cancer cells different with normal cells. When refers to ovarian cancer, malignant growth to distant metastasis to cytoreductive surgery to resurrected growth to uncontrollable metastasis seems to be a lethal cycle suffered most of ovarian cancer patients, especially for advanced stage strugglers. In past decades, many progresses have been observed in the biology research of ovarian cancer, including growth, apoptosis, autophagy, invasion, metastasis, metabolism, and angiogenesis [30, 31]. However, the molecular mechanisms underlying aggressive growth and metastasis of ovarian cancer cells still need further study.

Non coding RNAs, including long non coding RNAs and short non coding RNAs, are proved to involve in many biology of normal and cancer cells [32, 33]. Short non coding RNAs contain microRNAs (miRNAs), small interference RNAs (siRNAs) and PIWI protein binding RNAs (piRNAs) [34]. MiRNAs could play crucial roles as oncogene or antioncogene in human cancers. MiRNAs regulated cancer related growth, metabolism, genomic stability, apoptosis, epithelial to mesenchymal transition (EMT), tumor cell microenvironment and angiogenesis have been well demonstrated [35, 36]. Recently, decreased levels of miR-338-3p were observed in breast cancer, gastric cancer and esophageal squamous cell carcinoma compared to normal tissues, positively related with overall survival, and could serve as a poor prognostic marker, which indicated miR-338-3p might play as tumor suppressor in those malignant tumors [37–39]. Our previous report indicated miR-338-3p was downregulated in epithelial ovarian cancer tissues and was negatively correlated with MACC1 expression [14], but those results were observed from small enrolled patient numbers and single center cohort study. Thence, expression profile of miR-338-3p in ovarian cancer tissues still needs to be confirmed by other independent researches with large enrolled patient numbers. In present study, biomedical databases containing different independent cohorts with large enrolled patient numbers were queried to confirm the expression profile of miR-338-3p in ovarian cancer tissues. In the other hand, we also detected lower levels of miR-338-3p in ovarian cancer cells than normal ovary cells, which also were
confirmed by other two independent studies [12, 13]. Therefore, the expression profiles of miR-338-3p in ovarian cancer tissues and cancer cells were all downregulated, which indicated miR-338-3p might play an anti-tumor role in ovarian cancer.

Commonly, miRNAs were considered to bind to downstream target genes and inhibit gene transcription or induce gene degradation [40]. Multiply biomedical databases query and previous reports showed miR-338-3p could directly bind to MACC1 and inhibit MACC1 in different human cancer cells, which also was confirmed in present study by dual-luciferase reporter assay and western blot assay in ovarian cancer cells. Those results indicated that miR-338-3p could bind to and regulate MACC1 gene in ovarian cancer cells.

To examine the effects of miR-338-3p on the growth and metastasis of ovarian cancer cells, we overexpressed miR-338-3p in ovarian cancer OVCAR3 and OVCAR8 cells. Inhibition of proliferation, migration and invasion were observed following miR-338-3p restoration in vitro, which indicated miR-338-3p could suppress the growth and metastasis of ovarian cancer cells in vitro.

To explore the possible mechanism underlying miR-338-3p regulated growth and metastasis of ovarian cancer cells, we focused on MACC1, Met and its downstream signaling pathway. MACC1 were closely related to the invasion and metastasis, could be used as a prognostic marker for advanced colon cancer, gastric cancer, lung cancer and hepatocellular carcinoma, which also was proved in our previous reports in ovarian cancer [41–45]. MACC1 can regulate the expression of Met by binding to the sp1 site, which is about 60 bp upstream of the MET gene promoter [46, 47]. Met is the key factor of HGF/Met signaling, which is the most important regulator of EMT [48]. HGF/Met signaling can induce stromal cells to disrupt cell junctions, expose extracellular matrix, and promote growth, adhesion, migration, invasion and vascular endothelial cell growth of various malignant tumor cells, including ovarian cancer [49]. We found that MACC1 and Met was downregulated after miR-338-3p restoration, and miR-338-3p could attenuate the proliferation, migration and invasion induced by MACC1 or Met overexpression in present study, which might due to the inhibition of MACC1 by miR-338-3p and direct regulation of Met by miR-338-3p.

EMT can reduce the adhesion between cells and increase cells motility and invasiveness, and EMT also is demonstrated to play crucial roles in the invasion and metastasis of ovarian cancer and many other human cancers [50]. Human cancer related EMT is characterized with upregulation of the enzymes that decompose the extracellular matrix (such as MMPs) and mesenchymal markers (including Vimentin, Catenin beta and N-cadherin), and downregulation of epithelial markers (including E-cadherin and Cytokeratin7) [51]. PCNA usually serves as a canonical proliferation marker. Furthermore, downregulation of E-cadherin is considered as a hallmark of EMT [52]. Following restoration of miR-338-3p, PCNA, MMP2, MMP9, N-cadherin, Catenin beta and Vimentin were decreased, while E-cadherin and Cytokeratin7 were increased shown in our present data. MACC1 and Met overexpression induced upregulation of PCNA, MMP2, MMP9, N-cadherin, Catenin beta and Vimentin and downregulation of E-cadherin and Cytokeratin7 could be reversed by miR-338-3p, at least in partially. Those data indicated that overexpression of miR-338-3p could suppress the proliferation and EMT induced by MACC1 and Met overexpression in ovarian cancer cells.

Malignant growth and metastasis involve in many intricate and detailed signaling transductions in cancer cells. Once Met is activated, it can transmit extracellular signals to activate many intracellular pathways, including MAPK, PI3K, VEGF and PI3K signaling pathways, and participate in many physiological and pathological processes such as cell proliferation, apoptosis, migration and invasion [53]. We previously reported MACC1 might regulate MEK/ERK pathway to involve in the invasion and metastasis of ovarian cancer cells [41]. aberrant activation of canonical Wnt/Catenin beta pathway was also closely related with the proliferation, differentiation, motility, invasion and metastasis of normal and malignant tumor cells [54]. Wnt3a as a Wnt ligand is a main member of Wnt family, and p-LRP6 function as co-receptors for Wnt family and are required for the activation of canonical Wnt/Catenin beta signaling pathway [55]. Besides the KEGG pathway analysis results, our western blot data also showed expressions of Catenin beta and activities of Wnt/Catenin beta and MEK/ERK pathways in ovarian cancer cells, as well as MACC1 or Met upregulation induced expressions of Catenin beta and activities of Wnt/Catenin beta and MEK/ERK pathways in ovarian cancer cells, could be suppressed by miR-338-3p upregulation, which indicated that miR-338-3p could attenuate MACC1 or Met induced Wnt/Catenin beta and MEK/ERK signaling activities in ovarian cancer cells.

We also using xenograft mouse model to confirm the data explored in vitro. Upregulation of miR-338-3p could inhibit the xenograft tumor growth and metastasis in vivo. Decreased PCNA, MMP2, MMP9, Vimentin, Catenin beta and N-cadherin, increased E-cadherin and Cytokeratin7, and decreased activities of Wnt/Catenin beta and MEK/ERK pathways could be detected in miR-338-3p overexpression lentivectors transfected xenograft tumor tissues. These data indicated miR-338-3p could suppress the growth and metastasis of ovarian cancer.
cells via MACC1 and Met regulated Wnt/Catenin beta and MEK/ERK pathways in vivo.

Conclusions

Taken together, using database query and in vivo and in vitro assay, our study showed restoration of miR-338-3p could suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo, which was implicated in MACC1 and Met regulated Wnt/Catenin beta and MEK/ERK pathways. Our data might be helpful to elaborate the complicate molecular mechanisms and explore new therapy strategies for the ovarian cancer. However, the present study only investigated few parts of the regulation mechanisms of ovarian cancer malignant behaviors, further studies about the relations between miRNAs and malignant growth and metastasis of ovarian cancer still need to be performed.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13046-019-1494-3.

Additional file 1. KEGG Pathways Enrichment Analysis results.

Additional file 2. Target genes of miR-338-3p predicted by biomedical database.

Acknowledgements

We thank the Clinical Medicine Key Disciplines Laboratory of Henan Province and Department of Precision Medicine Center of the First Affiliated Hospital of Zhengzhou University for assistance with experiments.

Authors’ contributions

ZR participated in design of the study, carried out most of studies, drafted manuscript and performed statistical analysis. SH participated in design of the study and reviewed manuscript. TW, FW, CY and LG carried out RT-PCR, Western Blot, immunohistochemistry and participated in statistical analysis. LZ and ZW participated in database query, animal model work and helped to draft manuscript. All authors read and approved the final manuscript.

Funding

Our work was supported by the Key Scientific Research Projects of Advanced Education Institutions of Department of Education of Henan Province (2018A140001), a part from the Health and Family Planning Technology Overseas Training Project of Henan Province (2018028), and in part by the Youth Innovation Fund Project of the First Affiliated Hospital of Zhengzhou University (201418).

Availability of data and materials

The databases queried and/or analyzed in the present study are available in dbDEMC (www.pcb.ac.cn/dbDEMC/index.html), cbioPortal (https://www.cbioportal.org/), OncomirR (https://www.oncomir.org/), TargetScan Human (http://www.targetscan.org/vert_72/), miRPathDB (http://mrgp.bioinf.unibas.de/), microT-CDS (http://diana.mis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS/index), miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php), miTargetLink (https://ccb-web.cs unprotected) and ENCORI (http://starbase.sysu.edu.cn/) online websites.

Ethics approval and consent to participate

Animal experiment protocols performed in present study were approved by the ethics committee of the first affiliated hospital of Zhengzhou University.

Consent for publication

Not applicable.

Competing interests

The authors have declare that they have no competing interests.

Received: 19 September 2019 Accepted: 27 November 2019
Published online: 16 December 2019

References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
2. Konencny GE, Winterhoff B, Kolodka A, Hwang J, Masurier K, Dering J, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Cancer Res. 2011;71(6):1591–602.
3. Hananishi J, Manda M, Keda Y, Tomi M, Kawaguchi M, Kawai M, et al. Safety and antitumor activity of anti-EGFR antibody, NVK180, in patients with platinum-resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015–22.
4. Dzonz D, PARD, A. CDK4/6 targeted treatment in ovarian cancer. Lancet. 2017;390(10063):1591–6.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
6. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179–84.
7. Gieddke J, Ginde M, Camps J, Sokilde R, Kaczkowski B, Schetter AJ, et al. Rectal cancer microRNAome - microRNA expression in rectal Cancer and matched Normal mucosa. Clin Cancer Res. 2012;18(18):4919–30.
8. Guo B, Liu LY, Yao JY, Ma RL, Chang DM, Li ZF, et al. miR-338-3p suppresses gastric Cancer progression through a PTEN-AKT Axis by targeting P-REX2a. Mol Cancer Res. 2014;12(3):313–21.
9. Liu J, Cao LG, Zhao N, Feng Y, Yu Z, Li YH, et al. miR-338-3p inhibits A549 lung cancer cell proliferation and invasion by targeting AKT and beta-catenin signaling pathways. Mol Med Rep. 2019;20(1):33–40.
10. Chen X, Pan M, Han LL, Lu HT, Hao XW, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting P-REX2a. FEBS Lett. 2013;587(22):3729–37.
11. Zhang T, Liu W, Zeng XC, Jiang N, Fu BS, Guo Y, et al. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother. 2016;84:583–91.
12. Zhang Y, Shi B, Chen J, Hu L, Zhao C. MicroRNA-338-3p targets pyruvate kinase M2 and affects cell proliferation and metastasis of ovarian cancer. Am J Transl Res. 2016;8(7):2566–73.
13. Wen C, Liu X, Ma H, Zhang W, Li H. MicroRNA338 suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2. Int J Oncol. 2015;46(5):2277–85.
14. Zhang R, Shi H, Ren F, Liu Z, Ji P, Zhang W, et al. Down-regulation of miR-338-3p and up-regulation of MACC1 indicated poor prognosis of epithelial ovarian Cancer patients. J Cancer. 2019;10(6):1385–92.
15. Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao H, et al. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Res. 2017;45(D1):D128–D8.
16. Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cbioPortal. Sci Signal. 2013;6(269):pl1.
17. Wong NW, Chen YH, Chen S, Wang WX. OncomirR: an online resource for exploring pan-cancer microRNA dysregulation. Bioinform. 2018;34(4):713–5.
18. Hamberg M, Backes C, Fehlmann T, Hart M, Meder B, Meese E, et al. mirTargetLink-miRNAs, Genes and Interaction Networks. Int J Mol Sci. 2016;17(4):564.
19. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
20. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergeou T, Reczko M, et al. DIANA-microT web server v5.0: service integration into microRNA functional analysis workflows. Nucleic Acids Res. 2013;41(W1):W169–73.
21. Backes C, Kehl T, Stockel D, Fehlmann T, Schneider L, Meese E, et al. miPathDB: a new dictionary on microRNAs and target pathways. Nucleic Acids Res. 2017;45(D1):D90–D6.
22. Chou CT, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296–302.
23. Zhang RT, Shi HR, Liu XX, Zheng MH, Di YX, et al. Misregulation of poly-l-isoalkyl protein kinase 1, P53 and P21(WAF1) in epithelial ovarian cancer suggests poor prognosis. Oncol Rep. 2015;33(3):1235–42.
24. Huang N, Wu ZZ, Zhou MY, Wang L, Ma HR, Shi M, et al. Effect of MR-338-3p on epithelial-mesenchymal transition in gastric cancer cells by targeting EZB2 and MACC1 and regulation of MACC1/c-Met signaling. J Clin Oncol. 2014;32(15_suppl):e22010–e22010.
25. Shang C, Hong Y, Guo Y, Xue YX. MR-338-3p inhibits malignant biological behaviors of Glioma cells by targeting MACC1 gene. Med Sci Monitor. 2016; 22(7):10–1.
26. Zou T, Duan J, Liang JT, Shi JJ, Zou JT, Li H, et al. miR-338-3p suppresses colorectal cancer proliferation and progression by inhibiting MACC1. Int J Clin Exp Path. 2018;11(4):2556–67.
27. Lu ML, Huang H, Yang JH, Li J, Gao GF, Li WH, et al. miR-338-3p regulates colorectal cancer cell proliferation by targeting MACCC1. Exp Ther Med. 2017;14(2):2807–14.
28. Zhang CH, Li H, Wang J, Zhang JB, Hou QB. MicroRNA-338-3p suppresses cell proliferation, migration and invasion in human malignant melanoma by targeting MACCC1. Exp Ther Med. 2019;18(2):997–1004.
29. Hua FF, Li J, Liu SS, Zhu LH, Wang YH, Liang X, Ma N, et al. MRNA-338-3p regulates cervical cancer cells proliferation by targeting MACCC1 through MAPK signaling pathway. Eur Rev Med Pharmac. 2017;21(23):5342–52.
30. Jessom P, Boulanger T, Zhou W, Patwardhan P. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticanc. 2017; 17(5):427–37.
31. Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28:65–1.
32. Adelman K, Egan E. NON-CODING RNA more uses for genomic junk. Nat. 2016;530(7588):22.
33. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2010;10(10):723–37.
34. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94–101.
35. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Fosser R, Beig H, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004;543(7644):183–90.
36. Potempa S, Ridley AJ. Activation of both PKB and phosphatidylinositol 3-kinase by PKC delta is required for re-expression growth factor scatter factor-induced cellular re-adhesion and disassembly. Mol Biol Cell. 1998;9(6):2185–200.
37. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2005;21:781–810.
38. Kam K, Semenov A, Shuto Y, Spence R, Liu C, Matsuyama Y, et al. LDL-receptor-related protein 5 in Wnt signal transduction. Nat. 2000;407(6803):530–5.

Published online
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions